ICON Receives High Ranking in Independent Industry Survey
Dublin, Ireland, May 11th, 2009 – ICON plc,
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has again been named as a favourite Contract Research Organisation (CRO) to work with, according to a recent independent survey of pharmaceutical and biotechnology companies.
The fourth annual “CRO Industry Update”, conducted by William Blair & Company in association with CenterWatch, surveyed executives at 19 pharmaceutical and biotechnology companies regarding their experience with CROs and general trends affecting the CRO industry. ICON was among three CROs most frequently listed as sponsors’ favourite CRO in terms of quality, a result that is in line with ICON’s high rating in William Blair’s three previous CRO surveys. The report states that “ICON is consistently rated by our survey respondents as one of the highest-quality players in the space, despite its rapid growth,” and also describes how “this consistent quality bolsters our perception that ICON has one of the best growth profiles in the CRO industry, given its solid operations and relative size.”
The survey identified the most important metrics defining quality as budget maintenance, quality deliverables and delivery within timelines, followed by regulatory expertise, flexibility, customer service and low staff turnover.
Commenting on the results, Peter Gray, CEO ICON plc said “We are delighted to be consistently viewed by clients as a CRO that delivers quality service. We work extremely hard to maintain our quality standards and these survey results are testament to the great work and expertise of ICON employees. We remain committed to developing new ways to enable clients to bring their drugs and devices to market faster.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries.
Further information is available at
www.iconplc.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
